Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 225-Ac SSO110
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Details : 225-Ac SSO110 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
April 22, 2025
Lead Product(s) : 225-Ac SSO110
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Grants Orphan Drug Designation to Ariceum's Radiopharmaceutical Cancer Therapy
Details : 225Ac-SSO110 (225-Ac satoreotide tetraxetan) is the first somatostatin receptor 2 (SSTR2) antagonist labelled with Actinium-225 , it is being investigated in in patients with small cell lung cancer.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
February 06, 2025
FDA Clears Ariceum Therapeutics' 225Ac-Satoreotide for Small Cell Lung Cancer
Details : 225Ac-SSO110 is the first somatostatin receptor 2 (SSTR2) antagonist labelled with Actinium-225 , it is being investigated in in patients with small cell lung cancer or merkel cell carcinoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : 225-Ac Satoreotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Isotope Technologies Munich
Deal Size : Undisclosed
Deal Type : Agreement
ITM, Ariceum Enter Supply Agreement for Actinium-225 Medical Radioisotope
Details : Under the terms of the agreement, ITM will supply the therapeutic medical radioisotope, Ac-225 to advance the clinical development of SSO110 (225Ac-satoreotide tetraxetan) for treatment of neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : 225-Ac Satoreotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Isotope Technologies Munich
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 225-Ac Satoreotide Trizoxetan
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : NorthStar Medical Radioisotopes
Deal Size : Undisclosed
Deal Type : Agreement
Ariceum, NorthStar Partner On Actinium-225 Supply for Therapeutic Use
Details : Under the agreement, NorthStar will provide Ariceum with an Ac-225 radiolabelled compound. Ariceum will further develop SS0110 (Ac-225-satoreotide trizoxetan) for the treatment of SCLC.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : 225-Ac Satoreotide Trizoxetan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : NorthStar Medical Radioisotopes
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 177Lu-Satoreotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Eckert & Ziegler Strahlen
Deal Size : Undisclosed
Deal Type : Agreement
Ariceum, Eckert Sign Agreement for Radiotherapeutics Cancer Treatments
Details : Eckert & Ziegler will supply Ariceum with n.c.a. Ac-225 and Lu-177 used to radiolabel Ariceum's proprietary lead radiopharmaceutical drug SS0110 (satoreotide) targeting hard-to-treat cancers.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
December 05, 2024
Lead Product(s) : 177Lu-Satoreotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Eckert & Ziegler Strahlen
Deal Size : Undisclosed
Deal Type : Agreement
Ariceum Therapeutics Starts Phase 1 Trial in Patients with Recurrent Glioblastoma
Details : 123I-ATT001, is an Iodine-123 labelled PARP inhibitor, which is being investigated in patients with recurrent glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2024
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ariceum Granted UK Authorisation for Phase I Study of Iodine-123 in Glioblastoma
Details : ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ariceum Files for UK CTA for Iodine-123 PARP Inhibitor in Glioblastoma
Details : ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2024
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 177Lu-OPS201 (satoreotide) is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2023